QS Research · Michael Burry's Scion Capital analyst template · 2006
ZIMMER BIOMET HOLDINGS, INC. (ZBH)
As of 2026-11-17 · 12/15 boxes filled from SEC filings and market data
Report price $101.41 (close 2026-11-16); latest close $101.10 (2026-11-20), -0.3% since the report; figures re-marked at the latest close
Conclusion: PASS
Conviction low · base case +1% · downside -23% · upside +10%
At $101.41 the market is not paying for growth: 25.0x TTM earnings, near the five-year median of 25.3x, while the reverse DCF prices -8.0% annual revenue for a decade. Cash generation is attractive, with an 8.6% FCF yield and 4.32% net buyback yield, but ROIC of 5.0% sits below the 5.4% WACC, so the evidence supports a low-conviction PASS rather than a directional bet. The downside is -23.5% to $77.58 on -10.0% earnings at a compressed P/E of 21.25x (today 25.0x). The base is +0.8% to $102.22 with P/E at 25.2x, the peer median P/E across five peers. The upside is +10.0% to $111.55 on +10% earnings at today's P/E of 25x. Those outcomes frame a balanced range around today's price, leaving no strong edge.
Key numbers
- Share price: $101.10
- Market cap: $19.13B
- Latest financial period: TTM to Sep 30, 2026
- Revenue (TTM): $8.57B
- EV / EBITDA (TTM): 11.6x
- P/E (TTM): 24.9x
- FCF yield: 8.6%
- Price / book: 1.51x
- Earnings-quality flags (TTM): none flagged
- EV / FCF (TTM): 16.0x
- Revenue growth (latest fiscal year): +7.2%
- ROIC (TTM): 5.0%
- WACC: 5.4%
- Economic profit spread: -0.4 pts
The 15 boxes
- ✓ 1. Long-form business notes
Zimmer Biomet makes money selling orthopedic reconstructive, S.E.T., CMFT, bone cement, surgical and digital/robotic products, mainly through direct hospital/ASC accounts and distributors/dealers, with about 85% of 2025 net sales on consignment. The latest 10-K runs the business through Americas, EMEA and Asia Pacific; the U.S. is about 95% of Americas net sales and Japan about 50% of Asia Pacific. Revenue and operating income rose from $6.13B and $83.1M in FY2020 to $8.57B and $1.16B TTM to 2026-09-30; TTM operating cash flow was $1.88B, and TTM D&A was $1.11B including $669.2M of intangible amortization.
- ✓ 2. Competitive advantage
The sources name three scaled rivals — J&J MedTech (ex-DePuy Synthes), Stryker and Smith & Nephew — and put pricing on the same footing as technology, quality and reputation, so no pricing-power moat is documented. What the numbers show is scale and process, not a wide moat: revenue rose every year in the six-year table from $6.13B (FY2020) to $8.23B (FY2025) and $8.57B TTM, while operating income ran $83.1M in FY2020, $1.10B in FY2025 and $1.16B TTM, roughly 13% of revenue in the latest periods. The cash economics look better than the reported margin because intangible amortization ($665.9M FY2025, $669.2M TTM) and total D&A ($1.09B, $1.11B) absorb nearly all operating income, while capex is only $224.5M against $1.70B of operating cash flow in FY2025. Book returns stay low because $9.9B of goodwill and $4.7B of intangibles sit against $12.70B of total equity.
- ✓ 3. 10-Q takeaways
Q3 2026 net sales were $2,062.9 million, up 3.1% reported and 3.7% constant currency, with volume/mix +4.4%, pricing -0.7% and FX -0.6%; nine-month 2026 sales were $6,326.6 million, up 5.7% reported, 5.0% constant currency and 3.5% organic constant currency. Q3 2026 operating margin compressed to 14.9% from 17.6%, and net earnings fell to $191.6 million from $230.9 million largely on prior-year $55.1 million contingent-consideration adjustments, while adjusted diluted EPS was $1.90, flat year over year. Cash was $399.9 million at September 30, 2026, nine-month 2026 operating cash flow was $1,367.2 million, and nine-month buybacks were $579.3 million; FY2026 guidance was raised to 4.4%-4.9% reported revenue growth and $8.50-$8.60 adjusted diluted EPS. The 10-Q risk-factor section points back to the 2025 Form 10-K, while the computed 10-K diff shows 22 paragraphs with no counterpart in the prior report.
- ✓ 4. Corporate governance
Filled; members read this box.
- ✓ 5. Overview of the prior 3 years of 8-K filings
Filled; members read this box.
- ✓ 6. Other significant filings
Filled; members read this box.
- ✓ 7. Chronology of significant news and events
Filled; members read this box.
- ✓ 8. Comparables valuation interpretation
Filled; members read this box.
- ✓ 9. Insider trading interpretation
Filled; members read this box.
- ○ 10. Earnings-call notes
- ○ 11. Impression of the shareholder letter
- ○ 12. Scuttlebutt overview
- ✓ 13. Valuation and risk/reward summary
Filled; members read this box.
- ✓ 14. Current price suppression and potential catalysts
Filled; members read this box.
- ✓ 15. Conclusions
The call above.
Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.